“Our proprietary approach standardizes the tissue diagnostic process using contemporary spatial biology-enabling platforms,” said Paul Aiyetan, founder, CEO and director of NEOPATHOLOGY CORP. “Through this process, we are hoping to reduce diagnostic errors, improve diagnostic accuracy and expedite the time to treatment initiation. Thanks to TEDCO’s investment, we can continue progressing towards our goals.”

Join us for TEDCO’s 10th Entrepreneur Expo will be held Wednesday, December 4, 2024 at the Renaissance Baltimore Harborplace Hotel.

Revelo has developed a suite of products designed to capture, analyze and report on multiple metrics from various sources. With data collection, data analysis and data reporting capabilities, the Revelo integrates with several commercial business intelligence dashboards as well as open-source software. Their solution aims to offer flexible features at cost-efficient prices.

The startup world often flaunts explosive growth and billion-dollar exits. However, for founders identifying as socially and economically disadvantaged individuals (SEDI), the journey to success might require a more robust approach. Facing unique challenges in the funding landscape, SEDI-led companies must prioritize building strong foundations and sustainable growth over rapid expansion fueled by external capital.

“Simmbion’s innovative thinking could allow for continued advancement in the creation of synthetic cell technology and biologics,” said Jean-Luc Park, senior director of Social Impact Funds. “We look forward to seeing how their research and development support the continued growth of Maryland’s ecosystem and would like to extend the invitation to other technology start-ups from all industries to apply for TEDCO’s Funds.”